LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds, a Kentucky-based specialty pharmaceutical company, today announced that it is enrolling patients in a Phase III clinical trial, USWM-001, investigating the use of lofexidine hydrochloride (Lofexidine) for the treatment of opiate withdrawal symptoms in opiate dependent individuals. If approved by the Food and Drug Administration (FDA), Lofexidine would be the first non-addictive, non-narcotic treatment for relieving the distressing withdrawal symptoms associated with opiate detoxification approved in the United States.
